ProMIS Neurosciences Inc. financial data

Symbol
PMN on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Former names
AMORFIX LIFE SCIENCES LTD (to 11/3/2014)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 146 % +116%
Debt-to-equity 339 %
Return On Equity -587 % -210%
Return On Assets -134 % +70.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.9M shares +248%
Common Stock, Shares, Outstanding 19M shares +121%
Entity Public Float 29.7M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 19.8M shares +130%
Weighted Average Number of Shares Outstanding, Diluted 19.8M shares +130%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.12M USD -54%
General and Administrative Expense 5.67M USD -18.8%
Operating Income (Loss) -12.8M USD +43.1%
Nonoperating Income (Expense) 583K USD -70.2%
Net Income (Loss) Attributable to Parent -12.2M USD +40.5%
Earnings Per Share, Basic -0.54 USD/shares +79.2%
Earnings Per Share, Diluted -0.54 USD/shares +79.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 992K USD -18.8%
Assets, Current 1.41M USD -4.71%
Property, Plant and Equipment, Net 321 USD -93.1%
Intangible Assets, Net (Excluding Goodwill) 18K USD -17.1%
Assets 1.41M USD -5.91%
Accounts Payable, Current 2.02M USD -74.7%
Accrued Liabilities, Current 1.16M USD +49.1%
Liabilities, Current 3.17M USD -63.7%
Liabilities 3.69M USD -63.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -371K USD 0%
Retained Earnings (Accumulated Deficit) -99.7M USD -13.9%
Stockholders' Equity Attributable to Parent -2.28M USD +73.3%
Liabilities and Equity 1.41M USD -5.91%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.3M USD -302%
Net Cash Provided by (Used in) Financing Activities 190K USD
Common Stock, Shares, Issued 19M shares +121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.1M USD -297%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 992K USD -18.8%
Deferred Tax Assets, Valuation Allowance 27.7M USD +15.4%
Deferred Tax Assets, Gross 27.7M USD +15.4%
Depreciation 4.69K USD -81.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12M USD +42%
Property, Plant and Equipment, Gross 80.3K USD -4.45%
Deferred Tax Assets, Operating Loss Carryforwards 21.2M USD +20.1%
Preferred Stock, Shares Issued 1.17M shares -98.3%
Preferred Stock, Shares Authorized 70M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 97.8M USD +23.2%
Preferred Stock, Shares Outstanding 1.17M shares -98.3%
Amortization of Intangible Assets 4.99K USD -6.38%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 18K USD -86.6%
Interest Expense 76.8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares